NCT04734379View on ClinicalTrials.gov

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2023

Conditions
Progressive Supranuclear PalsyCorticobasal Syndrome
Interventions
DRUG

Fasudil

Oral fasudil 180 mg/day

Trial Locations (1)

94158

University of California Weill Institute for Neurosciences, San Francisco

Sponsors
All Listed Sponsors
lead

Woolsey Pharmaceuticals

INDUSTRY